New small molecules to block cancer growth and improve immune response
Official title: First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
Funded at University of Maryland Baltimore · NIH-11212390 · Data updated 2026-11-12
This study is looking at new small molecules that can help fight cancer by blocking how cancer cells grow and also boosting the immune system, which could lead to better treatments with fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | December 11, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $165,766 |
| NIH project number | 3R01CA285468-02S1 |
| Project ID | NIH-11212390 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are resistant to current therapies or those who have limited treatment options.
✕Less likely to help
Patients with early-stage cancers that are easily treatable with standard therapies may not receive significant benefit from this research.
What this research studies
This research focuses on developing innovative small molecules that can inhibit protein translation and an immune checkpoint simultaneously in cancer cells. By targeting multiple pathways essential for cancer progression, the approach aims to reduce the risk of drug resistance and minimize toxicity to normal tissues. The study will involve testing these small molecules in various cancer models to evaluate their effectiveness and safety. Patients may benefit from a more effective cancer treatment that combines precision medicine with broader action against cancer cell survival mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects.
How similar studies have gone: Other research has shown promise in targeting multiple pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Carrier, France — University of Maryland Baltimore
- Study coordinator: Carrier, France
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.